Media and News Releases

Upcoming and Past Events

Amarex Featured in 15-year Anniversary Issue of the NSF International Journal

24 Feb 2021

The just released Issue 48 of NSF International’s Health Science Journal features contributions by Amarex Clinical Research, LLC. This journal is available at


Severe-to-Critical COVID-19 Patient Clinical Trial Reaches Full Enrollment

18 Jan 2021

Our client’s Phase III clinical trial for patients with severe-to-critical COVID-19 symptoms reached full enrollment (390 patients) in mid-December. Data analysis results are expected this quarter. The trial was conducted in the U.S., Canada, and U.K.. 


New Drug Application to the U.S. FDA for Parkinson’s Treatment

19 Nov 2020

The regulatory department at Amarex Clinical Research, LLC, an NSF International company, recently submitted a new drug application (NDA) on behalf of its client. The Amarex team also wrote a substantial portion of the NDA and did the publishing.

U.S. FDA Grants Fast Track Designation to Amarex Client PRG S&T Inc.

22 Oct 2020

Amarex Clinical Research, LLC, an NSF International company announced that the U.S. FDA granted Fast Track designation to Amarex’s client PRG S&T Inc. for PRG’s drug Progerinin, being tested as a treatment for Hutchinson-Gilford Progeria Syndrome (HGPS) and Werner Syndrome (WS).

Amytrx Enrolling Clinical Trial of AMTX-100 in Patients with Atopic Dermatitis

08 Oct 2020

Amarex client, Amytrx Therapeutics (“Amytrx”), recently initiated clinical testing of their anti-inflammatory therapeutic product AMTX-100 for dermatological diseases and conditions with the enrollment of patients in a first-in-man Phase 1/2b study for treatment of mild to moderate atopic dermatitis.

Copy Of -Amarex to Support AIM ImmunoTech in Regulatory Filings for Exciting Pancreatic Cancer Treatment under Development

22 Sep 2020

Amarex Clinical Research, LLC (Amarex) client AIM ImmunoTech Inc. (NYSE American: AIM) today announced receipt of statistically significant positive pancreatic cancer survival results from a multi-year Early Access Program (EAP) conducted at Erasmus Medical Center in the Netherlands.

Now Enrolling for a Phase IIb Trial Treating Patients with HPV-Induced CIN2/3

21 Sep 2020

Amarex Clinical Research, LLC, an NSF International company announces its client, Frantz Viral Therapeutics, LLC, is now enrolling for their Phase IIb pivotal clinical trial of Artesunate Vaginal Inserts for the treatment of biopsy-proven HPV-associated cervical intraepithelial neoplasia 2/3 (CIN2/3) in adult female patients.

Amarex Receives SMP Letter from TFDA for an Oncology Drug Clinical Trial Treating Pancreatic Cancer

10 Sep 2020

Amarex Clinical Research, LLC, an NSF International company announces today that earlier this week they received a study may proceed (SMP) letter from the Taiwan Food & Drug Administration (TFDA) to conduct the first in human clinical trial of RP-72 in Taiwan. RP-72 is a 72 amino acid propriety recombinant protein antagonist for the CXCR1 and CXCR2 receptors of interleukin-8, a drug that treats pancreatic cancer. In early 2020, Amarex also received a SMP letter from the U.S. FDA for RP-72 to treat pancreatic cancer.

Amarex in the Fight Against COVID-19

02 Sep 2020

In early March, Amarex Clinical Research, LLC, an NSF International company began work on a potential treatment for Coronavirus Disease 2019. Since then, Amarex has helped 16 companies on 32 separate projects for COVID-19 products.

Phase 3 Trial for Patients with Severe-to-Critical COVID-19 Symptoms Reaches Enrollment Halfway Point

26 Aug 2020

Amarex Clinical Research, LLC, an NSF International company, announced today their client’s Phase 3 clinical trial for patients with severe-to-critical COVID-19 symptoms has reached the patient enrollment halfway point. Amarex’s team has managed the trial and will conduct the interim analysis.

Phase 2 Mild-to-Moderate COVID-19 Study Results for PRO 140

21 Aug 2020

Amarex Clinical Research, LLC, an NSF International company announced the completion of a Phase 2, randomized, double-blind, placebo-controlled clinical study evaluating efficacy and safety of PRO 140 (leronlimab) in patients with documented COVID-19 symptoms.

Amarex Highlighted in NSF International’s Latest Health Sciences Journal

06 Aug 2020

The just released Issue 47 of NSF International’s Health Science Journal features contributions by Amarex Clinical Research, LLC: 1) a white paper on Safety Risk Management; 2) an interview with visiting trainee from the Korean Ministry of Food and Drug Safety (MFDS); and 3) an overview of Amarex’s work on clinical products dealing with COVID-19 disease.

Congratulations to our client Akili Interactive on their recent approval!

25 Jun 2020


Learn more about this product approval here.

Amarex Client Now Enrolling Patients for a Blood Filtration Device Study Treating COVID-19 Patients Experiencing Septic Shock

02 Jun 2020

In April, Amarex Clinical Research, LLC, an NSF International company, achieved rapid, supplemental Investigation Device Exemption (IDE) approval from the U.S. FDA, on behalf of its client, to treat COVID-19 patients experiencing septic shock under an already underway Phase III clinical trial of a blood filtration device.

Amarex Co-Authors Paper on Emergency Use Treatment of Leronlimab for COVID-19

28 May 2020

In mid-March, Amarex worked with client CytoDyn to prepare, submit, and achieve FDA approval for emergency use of CytoDyn’s drug leronlimab as a treatment for severe cases of COVID-19. Since then, over 50 patients in a New York hospital have been treated with leronlimab. Initial results appear to show that leronlimab restores immune homeostasis, reduces plasma viral load, and reverses hyperimmune activation and inflammation in critically ill COVID-19 patients.

1 / 5

Please reload

Amarex Job Openings at the BioCapital Life Sciences Career Fair | Feb. 18, 2021

Amarex Clinical Research, LLC, an NSF International company, is featuring current job openings at the MD Tech Council BioCapital Life Sciences Career Fair, Thursday, February 18th. This virtual event is free and open to all students and job seekers interested in career opportunities in the life sciences industry.


Expand your career and be a part of something big. At Amarex we conduct clinical research to advance new, cutting-edge medical products that make a big difference by providing doctors with new treatments for their patients.


We have job openings in several disciplines, including: Clinical Operations, Data Management, Information Technology, Business Development, Medical Safety & Pharmacovigilance, Regulatory Affairs, and Statistics.


Register for this virtual event, visit our booth, and speak to an Amarex representative about expanding your career:

Enrichment Strategies to Increase the Power/Reduce the Sample Size in Clinical Trials

On January 07, 2021, Dr. Kazem Kazempour, President & CEO, conducted the webinar Enrichment Strategies to Increase the Power/Reduce the Sample Size in Clinical Trials.


Dr. Kazempour, an expert statistician, discussed the types of enrichment strategies that can be used to select study subjects more likely to detect drug effects. Enrichment strategies enhance the potential for trial success, reduce trial costs, decrease time to trial completion, and increase patient enrollment and retention. Dr. Kazempour discussed practical, prognostic, and predictive enrichment strategies. He also addressed the statistical impact of enrichment strategies on type I and type II error, suggested regulatory pathways for designing an enrichment trial, and suggested strategies for combining enrichment and adaptive trial design.

View the webinar recording on our YouTube channel.

Webinar Recording Available for Oncology Clinical Trials: An Emerging Paradigm Shift in Trial Design

On October 27, Dr. Kush Dhody, Senior Vice President of Clinical Operations, conducted the webinar Oncology Clinical Trials: An Emerging Paradigm Shift in Trial Design. The recording of this webinar is now available.   


Cancer treatments are fulfilling the promises of personalized medicine. One aspect is the use of biomarkers detectable in blood such as circulating tumor cells. This webinar reviews several newer clinical trial strategies such as combining adaptive trial designs with innovative endpoints; and umbrella or basket designs that allow multiple drugs to be tested against a cancer in a single trial, or a single drug to be tested against multiple cancer types in a single trial. Dr. Dhody also discusses the challenges of interpreting traditional survival analysis methods in this era of personalized cancer immunotherapies.

View the webinar recording on our YouTube channel.

Webinar Recording: Amarex in the Fight Against COVID-19

Dr. Kazem Kazempour, President & CEO of Amarex Clinical Research, LLC, an NSF International company presented a webinar highlighting Amarex’s COVID-19 work. Dr. Kazempour also discusses clinical trial regulatory activities around the globe, non-COVID-19 clinical trial activities, and emergency use authorizations (EUAs) for IVDs (including but not exclusive to COVID-19 trials).


View the webinar recording here.


Since March, Amarex has helped numerous companies with COVID-19 clinical product development (including device, diagnostic, drug, biologic, and vaccine products). Additionally, Amarex’s Regulatory department has executed applications and requests for compassionate use, emergency use, EUA, Clinical Trial Agreement, preIND meeting, eIND, fast track designation, and expanded access in the U.S., UK, Europe, and Asia.  

TFDA Seminar Recordings Available: FDA Approval Process for Digital Health Devices and EUA’s

On June 22, 2020, Dr. Kazem Kazempour, President & CEO, Amarex Taiwan, LLC and Dr. Chia-Hua Maggie Ho, COO of Amarex Taiwan, LLC gave a seminar to the Taiwan Food and Drug Administration (TFDA) titled U.S. FDA Approval Process for Digital Health Devices and Emergency Use Authorizations. Video recordings from the seminar are available for viewing. Topic summaries include:

Software as medical device (SaMD) is broadly defined as software intented to be used for one or more medical purposes, without being part of a hardware medical device. SaMD products vary in use and complexity, including image-reading software that runs on a smartphone to advanced artificial intelligence (AI) such as machine learning algorithms. This course introduces regulatory strategy and clinical evaluation required for market approval of software and AI-related medical products. Current international medical software regulation and risk management of AI medical products, and clinical evaluation of software as medical device are discussed.

During the COVID-19 pandemic, the FDA can use its emergency use authorization (EUA) authority to allow the use of unappoved medical products, or unapproved uses of approved medical products, to diagnose, treat, or prevent COVID-19 when certain criteria are met, including that there are no adequate, approved, and available alternatives. This training course explains FDA general recommendations and proceudres applicable to the authorization of the emergency use of COVID-19 diagnostic devices. 

View the course recordings here.

2020 Bio Innovation Conference | Oct. 5-6

Amarex Clinical Research, LLC, an NSF International company, will exhibit and present at the 2020 Bio Innovation Conference hosted by the Maryland Technology Council and held October 5-6.


The conference anticipates participation by 300 bioscience industry leaders involved in clinical product development and business success. Speakers will share experiences and information about best practices for clinical product business start-ups. Significant participation by international companies is expected. The two-day conference will be conducted online and includes presentations, panel discussions, live Q&A, and a one-on-one partnering program.


Amarex President & CEO, Dr. Kazem Kazempour, will present at Session C: Entrepreneurship Track, ‘Business Resiliency for the Unexpected and Expected’


Business resiliency implies ability to handle unexpected, difficult situations: lack of funding, a failed clinical trial, a surprise FDA audit, loss of a key employee, a lawsuit, stagnant sales, etc.; but it also means preparedness for achieving expected goals: licensing a product, raising funds, advancing the product, selling the product or business, etc. In this session a panel of entrepreneurs will share advice on business resiliency based on their business experiences.


Register for this conference at

KoNECT-MOHW-MFDS International Conference Virtual | Sep 9-11

Amarex Clinical Research, LLC, an NSF International company, is pleased to announce exhibiting at 2020 Korea National Enterprise for Clinical Trials (KoNECT) Ministry of Health and Welfare (MOHW) Ministry of Food and Drug Safety (MFDS) International Conference Virtual, held September 09-11. This year, the conference will be live-streamed online and offers presentations and workshops on new technologies and approaches to clinical trials in Asia, with a special focus on advanced regenerative medicine, biopharmaceuticals, and medical devices.


Register for this conference (and sign up for virtual partnering with us) at


Visit us at virtual booth #2:

Video Recording: Clinical Trials for Advanced Therapies

On 24 July 2020, Amarex Taiwan, LLC President & CEO, Dr. Kazem Kazempour, gave a keynote address at BioAsia-Taiwan 2020 titled Clinical Trials for Advanced Therapies. 


Dr. Kazempour discusses significant differences in trial design often needed for advanced therapy products (e.g., antibody or nucleic acid products), compared to designs for traditional, small molecule pharmaceutical products. Dr. Kazempour highlights special challenges for these trials, including sample size and power calculations to provide the optimal chance to demonstrate efficacy. Beyond design strategies, Dr. Kazempour reviews special expedited development support programs available from the U.S. FDA.

View the full recording here

Webinar Recording Available: Trial Design in General & Adaptive Trials in Particular

The full recording of our complimentary webinar, reviewing clinical trial design, is available here.

This webinar is presented by Amarex President & CEO, Dr. Kazem Kazempour. He addresses aspects of before study and after study clinical trial design. Physicians focus groups, KOL thoughts, selecting endpoints, IP management and distribution, site selection and patient recruitment are discussed. This webinar focuses specifically on the advantages and disadvantages of adapting a clinical trial.

Webinar Recording Available: Emergency Market Authorization of COVID-19 IVDs

The full recording of our complimentary webinar, reviewing insights into the Emergency Market Authorization of COVID-19 IVDs, is available on YouTube. 


This webinar covers emergency authorization applications for the E.U., the U.S., Asia, Australia and the World Health Organization. 

Learn from industry experts:


  • Robyn Meurant, Executive Director at NSF International. Before joining NSF, Robyn acted both as a professional officer and an advisor to the WHO and assisted with the development of the EUL for IVDs.

  • Chia-hua Maggie Ho, D. Phil., COO of Amarex Clinical Research, LLC, an NSF International Company. Dr. Ho specializes in APAC regulatory submission, clinical operations, business development and client services for the Pan-Pacific region. 


View the full webinar here.

Contact our experts, Robyn Murant, at, and Chia-hua Maggie Ho, at, or get in touch with our Business Development team.

Medical Device Training & Education Courses

Sign up for an NSF International medical device course and learn from experts at your own pace. Course offerings are available in auditing, premarket regulatory, quality system regulation and eLearning.

View the medical device training and education course offerings brochure.

To register for a course, or for more information, visit visit or contact

1 / 5

Please reload

  • Facebook Social Icon
  • Twitter Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon


           © 2021 Amarex Clinical Research, LLC, an NSF International company. All rights reserved.                                                                                                                                                                                                  Top of Page 

Contact     Subscribe     Privacy Policy     Clinical Site Registration     WebView

NSF Mark_100x100.jpg